WO2007123722A3 - Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse - Google Patents

Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse Download PDF

Info

Publication number
WO2007123722A3
WO2007123722A3 PCT/US2007/007965 US2007007965W WO2007123722A3 WO 2007123722 A3 WO2007123722 A3 WO 2007123722A3 US 2007007965 W US2007007965 W US 2007007965W WO 2007123722 A3 WO2007123722 A3 WO 2007123722A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
prognosis
prediction
methods
monitoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/007965
Other languages
English (en)
Other versions
WO2007123722A2 (fr
Inventor
Scott Wilhelm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Priority to CA002648106A priority Critical patent/CA2648106A1/fr
Priority to JP2009503038A priority patent/JP2009532029A/ja
Priority to EP07754481A priority patent/EP2002264A2/fr
Publication of WO2007123722A2 publication Critical patent/WO2007123722A2/fr
Publication of WO2007123722A3 publication Critical patent/WO2007123722A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne également les biomarqueurs et l'utilisation de biomarqueurs dans le cadre de la prévision et du pronostic d'un cancer, ainsi que l'utilisation de biomarqueurs en vue de surveiller l'efficacité d'un traitement anticancéreux.
PCT/US2007/007965 2006-03-31 2007-03-30 Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse Ceased WO2007123722A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002648106A CA2648106A1 (fr) 2006-03-31 2007-03-30 Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
JP2009503038A JP2009532029A (ja) 2006-03-31 2007-03-30 癌の予報および予後方法および癌治療のモニタリング
EP07754481A EP2002264A2 (fr) 2006-03-31 2007-03-30 Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78769306P 2006-03-31 2006-03-31
US60/787,693 2006-03-31
US90168207P 2007-02-16 2007-02-16
US60/901,682 2007-02-16

Publications (2)

Publication Number Publication Date
WO2007123722A2 WO2007123722A2 (fr) 2007-11-01
WO2007123722A3 true WO2007123722A3 (fr) 2008-05-08

Family

ID=38430446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007965 Ceased WO2007123722A2 (fr) 2006-03-31 2007-03-30 Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse

Country Status (4)

Country Link
EP (1) EP2002264A2 (fr)
JP (1) JP2009532029A (fr)
CA (1) CA2648106A1 (fr)
WO (1) WO2007123722A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
WO2004113274A2 (fr) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl-urees presentant une activite d'inhibition des kinases
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
MX2010005057A (es) * 2007-11-09 2010-05-19 Genentech Inc Metodos y composiciones para uso de diagnostico en pacientes de cancer.
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
WO2010022227A1 (fr) * 2008-08-20 2010-02-25 Schering Corporation Procédés pour surveiller une thérapie il-10
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
EP2989466B1 (fr) * 2013-04-25 2018-10-31 CBS Bioscience, Co., Ltd Procédé analytique pour augmenter la sensibilité d'une thérapie moléculaire ciblée dans un carcinome hépatocellulaire
US20190207946A1 (en) * 2016-12-20 2019-07-04 Google Inc. Conditional provision of access by interactive assistant modules
US11436417B2 (en) 2017-05-15 2022-09-06 Google Llc Providing access to user-controlled resources by automated assistants
CN112262381B (zh) 2018-08-07 2024-04-09 谷歌有限责任公司 汇编和评估对隐私问题的自动助理响应

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015947A2 (fr) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methodes et trousses pour la prediction du succes therapeutique, de la survie sans recidive et globale dans des therapies du cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015947A2 (fr) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Methodes et trousses pour la prediction du succes therapeutique, de la survie sans recidive et globale dans des therapies du cancer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH 1 OCT 2004, vol. 64, no. 19, 1 October 2004 (2004-10-01), pages 7099 - 7109, ISSN: 0008-5472 *
CARLOMAGNO FRANCESCA ET AL: "BAY 43-9006 inhibition of oncogenic RET mutants.", JOURNAL OF THE NATIONAL CANCER INSTITUTE 1 MAR 2006, vol. 98, no. 5, 1 March 2006 (2006-03-01), pages 326 - 334, XP002448750, ISSN: 1460-2105 *
CHANG YONG S ET AL: "Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.", CANCER CHEMOTHERAPY AND PHARMACOLOGY APR 2007, vol. 59, no. 5, April 2007 (2007-04-01), pages 561 - 574, XP002464783, ISSN: 0344-5704 *
CLARK JEFFREY W ET AL: "Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 AUG 2005, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5472 - 5480, XP002448749, ISSN: 1078-0432 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 October 2004 (2004-10-01), WILHELM SCOTT M ET AL: "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.", XP002448752, Database accession no. NLM15466206 *
HEIM MARTINA ET AL: "The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.", ANTI-CANCER DRUGS FEB 2005, vol. 16, no. 2, February 2005 (2005-02-01), pages 129 - 136, XP009088785, ISSN: 0959-4973 *
KUEFER R ET AL: "Translational research in renal cell cancer; Illustrated by the example of the vascular endothelial growth factor pathway", DER UROLOGE, AUSGABE A ; ZEITSCHRIFT FÜR KLINISCHE UND PRAKTISCHE UROLOGIE ORGAN DER DEUTSCHEN GESELLSCHAFT FÜR UROLOGIE, SPRINGER-VERLAG, BE, vol. 45, no. 3, 1 March 2006 (2006-03-01), pages 328 - 335, XP019321736, ISSN: 1433-0563 *
LUO ET AL: "Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 63, no. 2, 1 October 2005 (2005-10-01), pages 553 - 564, XP005077610, ISSN: 0360-3016 *
SHI Q ET AL: "Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NOV 1999, vol. 5, no. 11, November 1999 (1999-11-01), pages 3711 - 3721, XP002464785, ISSN: 1078-0432 *
TAMM M ET AL: "Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells.", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY OCT 1998, vol. 19, no. 4, October 1998 (1998-10-01), pages 653 - 661, XP002464787, ISSN: 1044-1549 *
WOUTERS BRADLY G ET AL: "Targeting hypoxia tolerance in cancer.", DRUG RESISTANCE UPDATES : REVIEWS AND COMMENTARIES IN ANTIMICROBIAL AND ANTICANCER CHEMOTHERAPY FEB 2004, vol. 7, no. 1, February 2004 (2004-02-01), pages 25 - 40, XP002464784, ISSN: 1368-7646 *
XU L ET AL: "Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells.", CANCER RESEARCH 15 NOV 1999, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5822 - 5829, XP002464786, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2007123722A2 (fr) 2007-11-01
EP2002264A2 (fr) 2008-12-17
JP2009532029A (ja) 2009-09-10
CA2648106A1 (fr) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2007123722A3 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
WO2007047955A3 (fr) Methodes de prevision et de pronostic du cancer, et surveillance d'une therapie anticancereuse
WO2007056012A3 (fr) Methodes pour la prevision et le pronostic du cancer, et pour la surveillance de therapie anticancereuse
WO2007059094A3 (fr) Procedes destines a predire et a pronostiquer un cancer, et suivi de la therapie du cancer
ZA200803516B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2010017515A3 (fr) Marqueurs spécifiques du cancer du sein et procédés d’utilisation
WO2009108860A8 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
WO2008153705A3 (fr) Procédés de traitement, de diagnostic et de détection de troubles liés à fgf21
WO2011037643A3 (fr) Compositions et procédés de détection et de traitement de carcinomes de la prostate
WO2010102195A3 (fr) Gène de l'annexine a11 et gènes associés en tant que biomarqueurs pour le cancer
WO2007141280A3 (fr) protéines
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
AU2009231892A8 (en) Methods of diagnosing, preventing and treating bone mass diseases
MY155340A (en) Use of cathepsin c
WO2010037042A3 (fr) Procédés pour détecter et traiter le cancer
WO2008115710A3 (fr) Biomarqueurs pour le cancer
WO2012078648A3 (fr) Nouvelle méthode de diagnostic et de pronostic du cancer et prédiction de la réponse à une thérapie
WO2008026008A8 (fr) Protéine
WO2009098451A3 (fr) Biomarqueurs d’inhibition d’aminopeptidase
WO2004028352A3 (fr) Techniques de prevision et de pronostic de cancer et surveillance de therapie anticancereuse
IL226362A0 (en) compounds, and methods for treating cancer
WO2006032009A3 (fr) Procedes de prevision et de pronostic du cancer et de suivi de la therapie du cancer
WO2008063957A3 (fr) Méthodes de traitement de troubles induits par des endotoxines
WO2012024302A3 (fr) Biomarqueurs du cancer
SG178929A1 (en) Use of cathepsin h

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754481

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009503038

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2648106

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007754481

Country of ref document: EP